RHOFADE™ 1% cream was approved by the U.S. Food and Drug Administration (FDA) in January 2017 for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
Rhofade, also known as oxymetazoline hydrochloride cream is applied to the skin to treat the persistent facial erythema (redness) caused by rosacea, as opposed to the other symptoms of rosacea, like easy flushing, red bumps and pus pimples, skin burning, and sensitivity, explains Dr. Joshua Zeichner, a New York City dermatologist.
While other rosacea medications, such as Finacea, MetroGel and Oracea, target the treatment of bumps and pimples caused by rosacea type 2, Rhofade is focused on treating the facial redness.
The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea. Persistent facial redness (or flushing) is cited as the most common sign of rosacea, and may resemble a sunburn that does not go away.
Typical triggers for rosacea flares include sun exposure, stress, weather, food, exercise and/or products.
In an survey of rosacea patients performed by the Rosacea Society, 65% of rosacea patients surveyed said their symptoms first appeared between 30-60 years of age.5
“Historically, there haven’t been many options available to help physicians address persistent facial erythema and often we ended up just helping our patients identify and manage triggers, which can lead to frustration for both the doctor and patient,” said Dr. Robert Weiss, Clinical Trial Investigator and Director of Maryland Laser, Skin & Vein Institute.
“With the approval of RHOFADE™, doctors will now be able to provide their patients with an effective once-daily treatment option to help manage this condition.”
FDA approval of Rhofade was based on the results of two clinical studies.